

Company Description

Vasomedical, Inc. is a diversified medical technology company specializing in the design, manufacture and sale of its proprietary medical devices and in the domestic sale of other OEM's diagnostic imaging products. The Company's businesses include the domestic sales representation of GE Healthcare diagnostic imaging products, GE Healthcare IT national value added reseller for radiology PACS software solutions, and the provision of External Counterpulsation (ECP) Therapy systems and other proprietary medical devices for hospitals, clinics and private physician practices worldwide. The Company's proprietary technology offered through its Enhanced External Counterpulsation (EECP®) Therapy systems is considered the gold standard in ECP therapy around the world. The Company also has a complete line of BIOX™ ECG Holter and ambulatory blood pressure monitoring products, as well as Mobicare wireless vital signs monitors.

Vasomedical's corporate headquarters are located in Westbury, NY. The Company's principal R&D and manufacturing facilities are located in Westbury, NY and China.

Operations by Subsidiary

- VasoHealthcare – a wholly owned subsidiary of Vasomedical that operates as a sales representative for GE Healthcare, the healthcare business unit of GE, for the sale of select GE Healthcare Diagnostic Imaging products. VasoHealthcare has been appointed to exclusively represent certain market segments in the 48 contiguous states of the United States and District of Columbia.
 - This representation business has generated annualized revenue in excess of \$25 million.
 - More than 80 full time medical device sales professionals.
 - Exclusive agreement extended through June 2015.
- VasoHealthcare IT - National value added reseller of GE Healthcare PACS solutions.
 - VasoHealthcare IT is in the startup phase.
- VasoSolutions - markets and provides Enhanced External Counterpulsation (EECP®) Therapy systems to hospitals, clinics and private physician practices, worldwide.
 - EECP® Therapy System – For non-invasive outpatient treatment that is FDA-cleared for four cardiac indications: angina, CHF, AMI and cardiogenic shock. EECP® Therapy is currently being offered to tens of thousands of patients every year in the US alone. EECP® Therapy systems are the only external counterpulsation systems that are clinically proven as documented in numerous peer reviewed papers.
- VasoGlobal – established to manage the operations of the Company's Chinese subsidiaries; as well as identify and manage potential international businesses the Company may consider. Current Chinese companies include:
 - Biox Instruments - A leading Company in ambulatory monitoring systems. Biox's products include ECG Holter recorders, ambulatory blood pressure monitoring (ABPM) systems, and analysis and reporting software for Holter and ABPM data. Biox products are FDA cleared, CE Marked and Health Canada Listed.
 - Life Enhancement Technology Limited (LET) - Established in 2004, LET is the manufacturing and engineering arm of VasoSolutions for its Enhanced External Counterpulsation (EECP®) Therapy systems, primarily for the international market.




At a Glance: (8/15/14)

Exchange: OTCBB
 Ticker: VASO
 Stock Price: \$0.26
 3 Month Avg. Vol.: 67,309
 52 Week Range: \$0.20-\$0.50
 Market Cap: \$40.5 mil
 Shares Outstanding: 155.7 mil

Investment Highlights

- Strong balance sheet with approximately \$10 million cash as of June 30, 2014
- VAR agreement with GE Healthcare IT signed in June 2014
- U.S. sales representation agreement with one of the largest diagnostic imaging companies, GE Healthcare
- Mobicare wireless multi-parameter patient monitoring systems launched in 2014
- Proprietary EECP® Therapy systems are accepted as the gold standard of ECP treatment
- Vasomedical currently controls approximately 70% of the global ECP market (estimates)
- Successfully acquired two China-based medical device companies in 2011, which expanded manufacturing capacity, product lines and R&D capability
- Chinese manufacturing of EECP® equipment increased control over IP, expanded presence in China and improved gross margins from EECP® sales
- Growth opportunities through new product lines, expansion into new territories and additional OEM agreements
- Vasomedical has repurchased approximately 10.3 million shares of common stock since April 2013

Our Global Presence



Company News

- 8/15/14 Vasomedical to Exhibit Proprietary Products at MEDICAL FAIR ASIA 2014 in Singapore
- 7/16/14 Vasomedical Signs Agreement with GEHC IT to Become National Value Added Reseller for Radiology PAC-Software Solutions
- 5/6/14 Vasomedical to Showcase Products in Brazil at HOSPITALAR
- 4/16/14 Vasomedical Announces Cooperative Agreement with PSK for International Marketing of ECP Systems
- 3/17/14 Vasomedical Announces Biox's MobiCare™ Wireless Patient Monitors Receives Marketing Approval in China
- 1/6/14 FDA Reclassifies ECP Devices for Refractory Angina as Class II

Management Team

Jun Ma, PhD
President & Chief Executive Officer

Michael J. Beecher, CPA
Chief Financial Officer

Randy Hill
Senior Vice President/ CEO VasoHealthcare

Jonathan P. Newton
Vice President of Finance & Controller


Qiuming Shen
President of Biox Instruments

Xichang Li
President of Life Enhancement Technology

Lawrence M. Liebman
Vice President of International Sales & Marketing VasoSolutions

David Nierle
Vice President of Sales VasoSolutions

Numbers in Graph



This fact sheet contains "forward-looking statements." These statements include words like "may," "expects," "believes," "plans," "scheduled," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Vasomedical to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Investor Contacts

Michael Beecher/ Amanda Jiang
212-508-5840
mbeecher@vasomedical.com / ajiang@vasomedical.com